Metformin, widely studied in diabetic and nondiabetic COVID‐19 patients, activates SIRT1 and AMPK pathways to reduce inflammation and enhance mitochondrial function, with systematic reviews and randomized controlled trials reporting decreased severity, hospitalization, and mortality rates, supporting its protective role in acute COVID‐19 [56, 57]. The gene discussed is SIRT1; the disease is COVID-19.